Virtual and CMC-Based Screening Identified Reticuline, an Intermediate of BIA Biosynthesis, as a Potential Agonist of D5R
Open Access
Abstract
Natural products represent an important reservoir for GPCR ligand discovery. In this study, we established an integrated workflow combining virtual screening, biophysical validation, functional signaling assays, and transcriptomic profiling to identify reticuline, a dopamine-derived intermediate from the genus of Stephania, as a potential agonist of dopamine D5 receptor (D5R). Molecular docking revealed that most dopamine-derived compounds along the BIA synthetic pathway exhibit predicted binding affinities for the D5R that are lower than that of dopamine. As expected, the reticuline–D5R complex has a favorable predicted binding affinity of −7.9 kcal/mol. As for binding validation, direct interaction between reticuline and D5R was experimentally confirmed using cell membrane chromatography (CMC) and bio-layer interferometry (BLI), yielding a dissociation constant of 1.07 μM. cAMP assay demonstrated that reticuline activates D5R-mediated Gs-cAMP increasement in a concentration-responsive manner, which exhibits agonist-like activity with an EC50 value of 0.07 μM. The transcriptomic profiling further revealed that reticuline treatment induces transcriptional reprogramming in D5R-overexpressing cells, with enrichment of pathways related to ribosome biogenesis, mitochondrial oxidative phosphorylation, and neurodegenerative diseases. In summary, this study demonstrates that reticuline acts as a potential D5R agonist and highlights a systematic natural product-GPCR discovery strategy integrating computational prediction, experimental validation, and transcriptome-level mechanistic exploration.Keywords
Funding Information
- National Key Research and Development Program of China (2025YFC3508601)
- Sichuan Provincial Administration of Traditional Chinese Medicine (/)
- Chinese Academy of Engineering (2025-XZ-116)
This publication has 52 references indexed in Scilit:
- ATF3 promotes ferroptosis by transcriptional repression of SLC7A11 in ischemic strokeBrain Research Bulletin, 2025
- Genetic and proteomic analysis identifies BAG3 as an amyloid-responsive regulator of neuronal proteostasisActa Neuropathologica, 2025
- The cellular and molecular targets of natural products against metabolic disorders: a translational approach to reach the bedsideMedcomm, 2024
- Genome-wide pan-GPCR cell libraries accelerate drug discoveryActa Pharmaceutica Sinica B, 2024
- Highly multiplexed bioactivity screening reveals human and microbiota metabolome-GPCRome interactionsCell, 2023
- Advances of antitumor drug discovery in traditional Chinese medicine and natural active products by using multi‐active components combinationMedicinal Research Reviews, 2023
- New opportunities and challenges of natural products research: When target identification meets single-cell multiomicsActa Pharmaceutica Sinica B, 2022
- Targeting cancer signaling pathways by natural products: Exploring promising anti-cancer agentsBiomedicine & Pharmacotherapy, 2022
- Therapeutic targets of natural products for the management of cardiovascular symptoms of coronavirus disease 2019Phytotherapy Research, 2021
- Structural insights into the human D1 and D2 dopamine receptor signaling complexesCell, 2021